Vermillion this week reported that fourth-quarter OVA1 sales increased 40 percent year over year in preliminary results.

During an earnings call following release of the results, however, CEO Gail Page said that the company has in recent quarters "observed a plateau in OVA1 growth" and suggested that reimbursement problems could be behind this slowdown.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.